Erck, former executive chairman of the company, has been an active member of Novavax‘s senior management team for the last year and has had experience in the biotechnology sector.
Prior to joining Novavax, Erck was the president and CEO of Iomai.
Before to Iomai, he worked as president and CEO of Procept, as vice president of Corporate Development at Integrated Genetics (now Genzyme), and in management positions within Baxter International.
Erckwill remain as a member of the Board of Directors.
Current Board member James Young will assume the position of chairman of the Board.
Gary Evans of Novavax’s Board of Directors said Erck and Young’s leadership skills and broad experience in drug development will be invaluable to Novavax as the company works to advance its infectious disease pipeline of virus-like particle (VLP) vaccine candidates.
Erck said he looks forward to working and collaborating with the team of employees at Novavax as they strive to bring new medical advances with vaccines for subjects with unmet medical needs.
Novavax has formed a joint venture CPL Biologicals with Cadila Pharmaceuticals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India.